Chitosan-based delivery systems for mucosal vaccines

Bibliography

• Neutra MR, Kozlowski PA. 2006;Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006;6(2):148-58
   PubMed Web of Science ®Google Scholar
• Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol 1987;7(4):265-76. Review
   PubMed Web of Science ®Google Scholar
• Jabbal-Gill I. Nasal vaccine innovation. J Drug Target 2010;18(10):771-86
   PubMed Web of Science ®Google Scholar
• Modlin JF. Poliomyelitis in the United States: the final chapter? JAMA 2004;292(14):1749-51
   PubMed Web of Science ®Google Scholar
• Pasetti MF, Simon JK, Sztein MB, Levine MM. Immunology of gut mucosal vaccines. Immunol Rev 2011;239(1):125-48
   PubMed Web of Science ®Google Scholar
• Kapikian AZ, Hoshino Y, Chanock RM, Perez-Schael I. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis 1996;174(Suppl 1):S65-72
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Haber P, Wise RP, Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 2005;294(21):2720-5
   PubMed Web of Science ®Google Scholar
• Times of India. First indigenous nasal vaccine for H1N1 is here. Available from: http://pune.aarogya.com/index.php/news-and-update/first-indigenous-nasal-vaccine-for-h1n1-is-here [Accessed 26 March 2012]
   Google Scholar
• Garg NK, Mangal S, Khambete H, Tyagi RK. Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers. Recent Pat Drug Deliv Formul 2010;4(2):114-28
   PubMedGoogle Scholar
• Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev 2010;62(1):59-82
   PubMed Web of Science ®Google Scholar
• Neutra MR, Frey A, Kraehenbuhl JP. Epithelial M cells: gateways for mucosal infection and immunization. Cell 1996;86(3):345-8; Review
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Schacker TW, Ruff LE, CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp Med 2004;200(6):749-59
   PubMed Web of Science ®Google Scholar
• Sztein MB. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica Serovar Typhi strains used as live oral vaccines in humans. Clin Infect Dis 2007;45(Suppl 1):S15-19
   PubMed Web of Science ®Google Scholar
• Roberts GAF. Chitin chemistry. The Macmillan Press Ltd; London: 1992
   Google Scholar
• Sogias IA, Williams AC, Khutoryanskiy VV. Why is chitosan mucoadhesive? Biomacromolecules 2008;9(7):1837-42
   PubMed Web of Science ®Google Scholar
• Mourya VK, Inamdar NN. Trimethyl chitosan and its applications in drug delivery. Mater Sci Mater Med 2009;20(5):1057-79
   PubMed Web of Science ®Google Scholar
• Kurita K. Chitin and chitosan: functional biopolymers from marine crustaceans. Marine Biotechnol 2006;8(3):203-26
   Google Scholar
• Sashiwa H, Kawasaki N, Nakayama A, Chemical modification of chitosan. Part 15: synthesis of novel chitosan derivatives by substitution of hydrophilic amine using N-carboxyethylchitosan ethyl ester as an intermediate. Carbohydr Res 2003;338(6):557-61
   PubMed Web of Science ®Google Scholar
• Bernkop-Schnurch A, Guggi D, Pinter Y. Thiolated chitosans: development and in vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system. J Control Release 2004;94(1):177-86
   PubMed Web of Science ®Google Scholar
• Roldo M, Hornof M, Caliceti P, Bernkop-Schnurch A. Mucoadhesive thiolated chitosans as platforms for oral controlled drug delivery: synthesis and in vitro evaluation. Eur J Pharm Biopharm 2004;57(1):115-21
   PubMed Web of Science ®Google Scholar
• Holme KR, Perlin AS. Chitosan N-sulfate. A water-soluble polyelectrolyte. Carbohydr Res 1997;302(1-2):7-12
   PubMed Web of Science ®Google Scholar
• Yan C, Chen D, Gu J, Preparation of N-Succinyl-chitosan and their physical-chemical properties as a novel excipient. Zakugaki Zasshi 2006;126(9):789-93; The Pharmaceutical Society of Japan
   PubMed Web of Science ®Google Scholar
• Mourya VK, Inamdar NN, Tiwari A. Carboxymethyl chitosan and its applications. Adv Mat Lett 2010;1(1):11-33
   Google Scholar
• Park IK, Ihm JE, Park YH, Galactosylated chitosan (GC)-graft-poly(vinyl pyrrolidone) (PVP) as hepatocyte-targeting DNA carrier. Preparation and physicochemical characterization of GC-graft-PVP/DNA complex (1). J Control Release 2003;86(2-3):349-59
   PubMed Web of Science ®Google Scholar
• Holappa J, Nevalainen T, Safin R, Novel water-soluble quaternary piperazine derivatives of chitosan: synthesis and characterization. Macromol Biosci 2006;6(2):139-44
   PubMed Web of Science ®Google Scholar
• Verheul RJ, Amidi M, van der Wal S, Synthesis, characterization and in vitro biological properties of O-methyl free N,N,N-trimethylated chitosan. Biomaterials 2008;29(27):3642-9
   PubMed Web of Science ®Google Scholar
• Thanou M, Florea BI, Langemeyer MW, N-trimethylated chitosan chloride (TMC) improves the intestinal permeation of the peptide drug buserelin in vitro (Caco-2 cells) and in vivo (rats). Pharm Res 2000;17(1):27-31
   PubMed Web of Science ®Google Scholar
• Hamman JH, Stander M, Kotze AF. Effect of the degree of quaternisation of N-trimethyl chitosan chloride on absorption enhancement: in vivo evaluation in rat nasal epithelia. Int J Pharm 2002;232(1-2):235-42
   PubMed Web of Science ®Google Scholar
• Senel S, Kas HS, Squier CA. Application of chitosan in dental drug delivery and therapy. In: Muzzarelli RAA, editor. Chitosan per os: from dietary supplement to drug carrier. Arec.Grottammare; Italy: 2000. p. 241-56
   Google Scholar
• Senel S, McClure SJ. Potential applications of chitosan in veterinary medicine. Adv Drug Deliv Rev 2004;56(10):1467-80
   PubMed Web of Science ®Google Scholar
• Snyman D, Hamman JH, Kotze AF. Evaluation of the mucoadhesive properties of N-trimethyl chitosan chloride. Drug Dev Ind Pharm 2003;29(1):61-9
   PubMed Web of Science ®Google Scholar
• Soane RJ, Hinchcliffe M, Davis SS, Illum L. Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm 2001;217(1-2):183-91
   PubMed Web of Science ®Google Scholar
• Soane RJ, Frier M, Perkins AC, Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 1999;178:55-65
   PubMed Web of Science ®Google Scholar
• Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994;11(9):1358-61
   PubMed Web of Science ®Google Scholar
• Dodane V, Amin Khan M, Merwin JR. Effect of chitosan on epithelial permeability and structure. Int J Pharm 1999;182:21-32
   PubMed Web of Science ®Google Scholar
• Wu Y, Wei W, Zhou M, Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization. Biomaterials 2012;33(7):2351-60
   PubMed Web of Science ®Google Scholar
• Illum L, Jabbal-Gill I, Hinchcliffe M, Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001;51(1-3):81-96
   PubMed Web of Science ®Google Scholar
• Ghendon Y, Markushin S, Vasiliev Y, Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally. J Med Virol 2009;81(3):494-506
   PubMed Web of Science ®Google Scholar
• Arca HC, Gunbeyaz M, Senel S. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev Vaccines 2009;8(7):937-53
   PubMed Web of Science ®Google Scholar
• Senel S. Chitosan-based particulate systems for non-invasive vaccine delivery. Adv Polym Sci 2011;243:111-38
   Web of Science ®Google Scholar
• Mills KH. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 2008;38(10):2636-49
   PubMed Web of Science ®Google Scholar
• Jabbal-Gill I, Fisher AN, Rappuoli R, Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 1998;16(20):2039-46
   PubMed Web of Science ®Google Scholar
• McNeela EA, O'Connor D, Jabbal-Gill I, A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 2001;19(9-10):1188-98
   Web of Science ®Google Scholar
• Bacon A, Makin J, Sizer PJ, Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun 2000;68:5764-70
   PubMed Web of Science ®Google Scholar
• Hagenaars N, Verheul RJ, Mooren I, Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine. J Control Release 2009;140(2):126-33
   PubMed Web of Science ®Google Scholar
• Svindland SC, Jul-Larsen A, Pathirana R, The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine. Influenza Other Respi Viruses 2012;6(2):90-100
   PubMed Web of Science ®Google Scholar
• Rauw F, Gardin Y, Palya V, The positive adjuvant effect of chitosan on antigen-specific cell-mediated immunity after chickens vaccination with live Newcastle disease vaccine. Vet Immunol Immunopathol 2010;134(3-4):249-58
   PubMed Web of Science ®Google Scholar
• Rauw F, Gardin Y, Palya V, Improved vaccination against Newcastle disease by an in ovo recombinant HVT-ND combined with an adjuvanted live vaccine at day-old. Vaccine 2010;28(3):823-33
   PubMed Web of Science ®Google Scholar
• Xie Y, Zhou NJ, Gong YF, Th immune response induced by H pylori vaccine with chitosan as adjuvant and its relation to immune protection. World J Gastroenterol 2007;13(10):1547-53
   PubMed Web of Science ®Google Scholar
• McNeela EA, Jabbal-Gill I, Illum L, Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 2004;22(8):909-14
   PubMed Web of Science ®Google Scholar
• Read RC, Naylor SC, Potter CW, Effective nasal influenza vaccine delivery using chitosan. Vaccine 2005;23:4367-74
   PubMed Web of Science ®Google Scholar
• European Commission FP7 programme. Available from: http://cordis.europa.eu
   Google Scholar
• Hagenaars N, Mania M, de Jong P, Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine. J Control Release 2010;144(1):17-24
   PubMed Web of Science ®Google Scholar
• Wimer-Mackin S, Hinchcliffe M, Petrie CR, An intranasal vaccine targeting both the bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Vaccine 2006;24(18):3953-63
   PubMed Web of Science ®Google Scholar
• El-Kamary SS, Pasetti MF, Mendelman PM, Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis 2010;202(11):1649-58. Erratum in: J Infect Dis. 2011;203(7):1036
   PubMed Web of Science ®Google Scholar
• Amidi M, Pellikaan HC, Hirschberg H, Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs. Vaccine 2007;25(37-38):6818-29
   PubMed Web of Science ®Google Scholar
• Mills KH, Cosgrove C, McNeela EA, Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin A. Infect Immun 2003;71:726-32
   PubMed Web of Science ®Google Scholar
• Alleman E, Grrny R, Doelker E. Drug-laoded nanoparticles – preparation methods and drug targeting issues. Eur J Pharm Sci 1993;4:23-31
   Google Scholar
• Tiyaboonchai W, Woiszwillo J, Middaugh CR. Formulation and characterization of DNA-polyethylenimine-dextran sulfate nanoparticles. Eur J Pharm Sci 2003;19(4):191-202
   PubMed Web of Science ®Google Scholar
• Nagpal K, Singh SK, Mishra DN. Chitosan nanoparticles: a promising system in novel drug delivery. Chem Pharm Bull (Tokyo) 2010;58(11):1423-30
   PubMed Web of Science ®Google Scholar
• Pan Y, Li YJ, Zhao HY, Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 2002;249(1-2):139-47
   PubMed Web of Science ®Google Scholar
• Tiyaboonchai W, Limpeanchob N. Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles. Int J Pharm 2007;329(1-2):142-9
   PubMed Web of Science ®Google Scholar
• Erbacher P, Zou S, Bettinger T, Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharm Res 1998;15(9):1332-9
   PubMed Web of Science ®Google Scholar
• Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 1997;14(10):1431-6
   PubMed Web of Science ®Google Scholar
• Tang ZX, Qian JQ, Shi LE. Preparation of chitosan nanoparticles as carrier for immobilized enzyme. Appl Biochem Biotechnol 2007;136(1):77-96
   PubMed Web of Science ®Google Scholar
• Jiang HL, Kang ML, Quan JS, The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization. Biomaterials 2008;29(12):1931-9
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, Singh M, Ulmer JB. Microparticle-based technologies for vaccines. Methods 2006;40(1):10-19; Review
   PubMed Web of Science ®Google Scholar
• Nagamoto T, Hattori Y, Takayama K, Maitani Y. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm Res 2004;21(4):671-4
   PubMed Web of Science ®Google Scholar
• Gunbeyaz M, Faraji A, Ozkul A, Chitosan based delivery systems for mucosal immunization against bovine herpesvirus 1 (BHV-1). Eur J Pharm Sci 2010;41(3-4):531-45
   PubMed Web of Science ®Google Scholar
• Slutter B, Plapied L, Fievez V, Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J Control Release 2009;138(2):113-21
   PubMed Web of Science ®Google Scholar
• Kotze AF, Thanou MM, Luessen HL, Effect of the degree of quaternization of N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). Eur J Pharm Biopharm 1999;47(3):269-74
   PubMed Web of Science ®Google Scholar
• Sayin B, Somavarapu S, Li XW, TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines. Eur J Pharm Sci 2009;38(4):362-9
   PubMed Web of Science ®Google Scholar
• Slutter B, Bal S, Keijzer C, Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 2010;28(38):6282-91
   PubMed Web of Science ®Google Scholar
• Keijzer C, van der Zee R, van Eden W, PLGA, PLGA-TMC and TMC-TPP nanaoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. PLoS One 2011;46:11
   Google Scholar
• Vila A, Sanchez A, Janes K, Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm 2004;57(1):123-31
   PubMed Web of Science ®Google Scholar
• Borges O, Cordeiro-da-Silva A, Romeijn SG, Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J Control Release 2006;114(3):348-58
   PubMed Web of Science ®Google Scholar
• Shahiwala A, Vyas TK, Amiji MM. Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat Drug Deliv Formul 2007;1(1):1-9; Review
   PubMedGoogle Scholar
• Ahire VJ, Sawant KK, Doshi JB, Ravetkar SD. Chitosan microparticles as oral delivery system for tetanus toxoid. Drug Dev Ind Pharm 2007;33(10):1112-24
   PubMed Web of Science ®Google Scholar
• Pokharkar V, Bhumkar D, Suresh K, Gold nanoparticles as a potential carrier for transmucosal vaccine delivery. J Biomed Nanotechnol 2011;7(1):57-9
   PubMed Web of Science ®Google Scholar
• Chen F, Zhang ZR, Yuan F, In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery. Int J Pharm 2008;349(1-2):226-33
   PubMed Web of Science ®Google Scholar
• Borges O, Tavares J, de Sousa A, Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur J Pharm Sci 2007;32(4-5):278-90
   PubMed Web of Science ®Google Scholar
• Hori M, Onishi H, Machida Y. Evaluation of Eudragit-coated chitosan microparticles as an oral immune delivery system. Int J Pharm 2005;297(1-2):223-34
   PubMed Web of Science ®Google Scholar
• Debache K, Kropf C, Schutz CA, Vaccination of mice with chitosan nanogel-associated recombinant NcPDI against challenge infection with neospora caninum tachyzoites. Parasite Immunol 2011;33(2):81-94
   PubMed Web of Science ®Google Scholar
• Gupta RK, Relyveld EH, Lindblad EB, Adjuvants–a balance between toxicity and adjuvanticity. Vaccine 1993;11(3):293-306
   PubMed Web of Science ®Google Scholar
• Klas SD, Petrie CR, Warwood SJ, A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge. Vaccine 2008;26(43):5494-502
   PubMed Web of Science ®Google Scholar
• Atmar RL, Bernstein DI, Harro CD, Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 2011;365(23):2178-87
   PubMed Web of Science ®Google Scholar
• Borges O, Cordeiro-da-Silva A, Tavares J, Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur J Pharm Biopharm 2008;69(2):405-16
   PubMed Web of Science ®Google Scholar
• Yue Y, Xu W, Hu L, Enhanced resistance to coxsackievirus B3-induced myocarditis by intranasal co-immunization of lymphotactin gene encapsulated in chitosan particle. Virology 2009;386(2):438-47
   PubMed Web of Science ®Google Scholar
• Moschos SA, Bramwell VW, Somavarapu S, Alpar HO. Adjuvant synergy: the effects of nasal coadministration of adjuvants. Immunol Cell Biol 2004;82(6):628-37
   PubMed Web of Science ®Google Scholar
• Iqbal M, Lin W, Jabbal-Gill I, Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 2003;21(13-14):1478-85
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang X, Kang Y, Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus. Vaccine 2008;26(40):5135-44
   PubMed Web of Science ®Google Scholar
• Khatri K, Goyal AK, Gupta PN, Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine 2008;26(18):2225-33
   PubMed Web of Science ®Google Scholar
• Xu J, Dai W, Wang Z, Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen A protects mice against nasopharyngeal colonization by streptococcus pneumoniae. Clin. Vaccine Immunol 2011;18(1):75-81
   PubMed Web of Science ®Google Scholar
• Yu M, Vajdy M. Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes. Expert Opin Biol Ther 2010;10(8):1181-95
   PubMed Web of Science ®Google Scholar
• Senel S. Applications of chitosan and its derivatives in veterinary medicine. In: Se-Kwon K, editor. Chitin, chitosan, oligosaccharides and their derivatives biological activities and applications. CRC Press; South Korea: 2010. p. 461-78
   Google Scholar
• Kang ML, Kang SG, Jiang HL, Chitosan microspheres containing Bordetella bronchiseptica antigens as novel vaccine against atrophic rhinitis in pigs. J Microbiol Biotechnol 2008;18(6):1179-85
   PubMed Web of Science ®Google Scholar
• Cokcaliskan C, Gursoy RN, Gunbeyaz M. Chitosan for mucosal immunization against foot and mouth disease. Presented at: 35th Annual Meeting and Exposition of the Controlled Release Society; 12 – 16 July 2008; New York, USA
   Google Scholar
• MUCOVAC2: Phase I clinical trial to assess the safety and immunogenicity of three HIV CN54gp140 immunisations administered through the intramuscular, intranasal and intravaginal routes in healthy female volunteers. Available from: http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=11679 http://www.iavireport.org/archives/2012/pages/IAVI-Report-16(1)-Vaccine-Briefs.aspx [Both accessed 27 March 2012]
   Google Scholar
• Pawar D, Goyal AK, Mangal S, Evaluation of mucoadhesive PLGA microparticles for nasal immunization. AAPS J 2010;12(2):130-7
   PubMed Web of Science ®Google Scholar
• Gupta NK, Tomar P, Sharma V, Dixit VK. Development and characterization of chitosan coated poly-(ε-caprolactone) nanoparticulate system for effective immunization against influenza. Vaccine 2011;29(48):9026-37
   PubMed Web of Science ®Google Scholar
• Slutter B, Jiskoot W. Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination. J Control Release 2010;148(1):117-21
   PubMed Web of Science ®Google Scholar
• Verheul RJ, Slutter B, Bal SM, Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for intranasal and intradermal vaccination. J Control Release 2011;156(1):46-52
   PubMed Web of Science ®Google Scholar
• Bal SM, Slutter B, Verheul R, Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice. Eur J Pharm Sci 2012;45(4):475-81
   PubMed Web of Science ®Google Scholar
• Sayin B, Somavarapu S, Li XW, Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Int J Pharm 2008;363(1-2):139-48
   PubMed Web of Science ®Google Scholar